867330-72-1

Basic information

• Product Name: 1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-
• Synonyms: 1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-;7-(2-Chloro-5-Methoxyphenyl)-5-Methyl-1,2,4-benzotriazin-3-aMine
• CAS NO: 867330-72-1
• Molecular Formula: C₁₅H₁₃ClN₄O
• Molecular Weight: 300.74292
• Product Categories: Amines, Aromatics, Miscellaneous Reagents, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 867330-72-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-(867330-72-1)
• EPA Substance Registry System: 1,2,4-Benzotriazin-3-aMine, 7-(2-chloro-5-Methoxyphenyl)-5-Methyl-(867330-72-1)

Safety Data

• Hazardous Substances Data: 867330-72-1(Hazardous Substances Data)

Usage

Description

1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-methoxyphenyl)-5-methylis a chemical compound with a unique structure that features a benzotriazine core, a 2-chloro-5-methoxyphenyl group, and a methyl group. 1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-methoxyphenyl)-5-methylhas potential applications in the pharmaceutical industry due to its ability to inhibit specific kinases, which are enzymes that play a crucial role in cell signaling and regulation.

Uses

Used in Pharmaceutical Industry:
1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-methoxyphenyl)-5-methylis used as a precursor in the preparation of Src kinase inhibitors, which are compounds that show antitumor activity. These inhibitors can potentially be used in the development of targeted cancer therapies, as they can specifically target and inhibit the activity of Src kinases, which are often overactive in various types of cancer.
Used in Therapeutic Treatment of Age-Related Illnesses:
1,2,4-Benzotriazin-3-amine, 7-(2-chloro-5-methoxyphenyl)-5-methylis also used in the synthesis of a topically administered agent for the therapeutic treatment of age-related illnesses. This application takes advantage of the compound's ability to modulate cellular processes and potentially slow down or reverse the effects of aging on the body. By developing a topically administered agent, it may be possible to provide a non-invasive and convenient treatment option for individuals suffering from age-related conditions.

Upstream product

• 867330-26-5 7-bromo-5-methyl-1,2,4-benzotriazin-3-ylamine 
• 89694-46-2 2-chloro-5-methoxyphenylboronic acid 
• 677297-87-9 7-bromo-5-methylbenzo[1,2,4]triazin-3-ylamine 1-oxide 
• 77811-44-0 4-bromo-2-methyl-6-nitroaniline 

Downstream Products

• 867331-63-3 7-(2-chloro-5-methoxyphenyl)-5-methyl-N-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-1,2,4-benzotriazin-3-ylamine 
• 867331-09-7 3-(3-amino-5-methyl-benzo[1,2,4]triazin-7-yl)-4-chloro-phenol 
• 867331-06-4 4-{[7-(2-chloro-5-methoxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino}-N-(2-pyrrolidin-1-ylethyl)benzenesulfonamide 
• 867331-41-7 benzyl 4-[(4-{[7-(2-chloro-5-methoxyphenyl)-5-methyl-1,2,4-benzotriazin-3-yl]amino}phenyl)sulfonyl]piperidine-1-carboxylate 

Relevant articles and documents

Development of prodrug 4-chloro-3-(5-methyl-3-{[4-(2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotriazin-7-yl)phenyl benzoate (TG100801): A topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degene

Age-related macular degeneration (AMD) is one of the leading causes of loss of vision in the industrialized world. Attenuating the VEGF signal in the eye to treat AMD has been validated clinically. A large body of evidence suggests that inhibitors targeti

Benzotriazine inhibitors of kinases

The invention provides benzotriazine compounds having formula (I). The benzotriazine compounds of the invention are capable of inhibiting kinases, such members of the Src kinase family, and various other specific receptor and non-receptor kinases.